Walleye Capital’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$96.1K Buy
289
+277
+2,308% +$95.9K ﹤0.01% 5213
2026
Q2
$4.46K Sell
12
-342
-97% -$102K ﹤0.01% 4545
2026
Q1
$91.4K Buy
+354
New +$94.2K ﹤0.01% 3701
2024
Q4
– Sell
-97
Closed -$17.2K – 5212
2024
Q3
$17.7K Buy
+97
New +$18.7K ﹤0.01% 4839

Other funds holding KRYS

Walleye Capital's KRYS Position: Q3 2026 in Review

Walleye Capital increased its Krystal Biotech (KRYS) stake by 2,308% in Q3 2026, buying an estimated $95.9K and bringing the position to 289 shares worth $96.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5213.

Walleye Capital first reported a position in KRYS in Q3 2024 and has held it in 4 quarters since. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Walleye Capital held 289 shares of Krystal Biotech worth $96.1K as of Q3 2026.
  • Walleye Capital bought 277 Krystal Biotech shares in Q3 2026, an estimated $95.9K.
  • Krystal Biotech made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5213 holding.
  • Walleye Capital first reported a position in Krystal Biotech in Q3 2024 and has held it in 4 quarters since.
  • 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.